{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-21-003475","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.943998+00:00","generated_at":"2026-06-28T09:53:21.824913+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"medium","headline":"Chemomab Therapeutics files updated corporate presentation on November 10, 2021","bullets":["Filed Form 8-K on Nov 10, 2021, including Items 7.01 (Regulation FD) and 9.01 (Exhibits).","Attached updated corporate presentation as Exhibit 99.1, highlighting treatments for fibrotic diseases.","Company based in Kiryat Atidim, Tel Aviv, with ADS trading on Nasdaq under ticker CMMB."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-21-003475","json":"https://secwatch.observer/filing/0001178913-21-003475.json","markdown":"https://secwatch.observer/filing/0001178913-21-003475.md","text":"https://secwatch.observer/filing/0001178913-21-003475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003475/0001178913-21-003475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003475/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:53:21.824913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}